METAOD004: A Phase IIa (double-blind, placebo-controlled, dose escalation) safety study with multiple daily doses (9, 27 or 54 mg AOD9604) administered orally (capsules) for seven days in 36 healthy clinically obese males presenting with a BMI 30 kg/m 2
Healthcare providers must check if youre eligible and screen for reasons you shouldnt get it before starting therapy
FIGURE 1 3.2 Daphnetin attenuated oxidative stress of diabetes cognitive dysfunction rats As shown in Figure 2, STZ-treated caused oxidative stress in rat brain, which increased the MDA content and GSSH content, and reduced the levels of SOD, CAT, GSH, Gpx and TAC, while daphnetin-treated inhibited these changes in oxidative stress-related medicators, which indicated that daphnetin could mitigate oxidative stress of diabetes cognitive dysfunction rats
Get Started Today
Oral supplements can help maintain levels over time, while IV therapy provides a direct boost for individuals with higher oxidative stress